Study	I^2		Odds Ratio (95% CrI)

Chemotherapy vs Afatinib

57			6.4e+07 (0.00065, 6.2e+18)
Pooled (pair−wise)			4.0e+06 (1.8, 3.4e+22)
Indirect (back−calculated)			1.5 (0.028, 86.)
Pooled (network)	44.4%		2.2 (0.055, 1.5e+02)

Erlotinib vs Afatinib

38			1.4 (0.28, 6.9)
Pooled (pair−wise)			1.3 (0.072, 27.)
Indirect (back−calculated)			1.0e+04 (0.15, 7.6e+08)
Pooled (network)	61.8%		2.4 (0.18, 56.)

Placebo vs Afatinib

54			0.32 (0.020, 4.8)
Pooled (pair−wise)			0.34 (0.0064, 9.3)
Indirect (back−calculated)			1.6 (0.0096, 2.8e+02)
Pooled (network)	0.0%		0.57 (0.026, 9.9)

Gefitinib vs Almonertinib

4			3.8e+07 (1.2e−05, 1.2e+20)
Pooled (pair−wise)			1.3e+06 (0.81, 4.8e+17)
Indirect (back−calculated)			NA
Pooled (network)			5.7e+05 (0.35, 8.7e+24)

Lazertinib vs Amivantamab_Lazertinib

r1			0.72 (0.0045, 1.2e+02)
Pooled (pair−wise)			0.80 (0.0031, 2.0e+02)
Indirect (back−calculated)			NA
Pooled (network)			1.7 (0.037, 91.)

0.1   1   10

Study	I^2		Odds Ratio (95% CrI)

Osimertinib vs Amivantamab_Lazertinib

r1			2.9 (0.43, 19.)
Pooled (pair–wise)			2.8 (0.13, 63.)
Indirect (back–calculated)			NA
Pooled (network)			1.9 (0.049, 62.)

Erlotinib vs Chemotherapy

51			3.6e−12 (3.5e−29, 3.8e+05)
Pooled (pair–wise)			2.5e−10 (3.0e−34, 0.62)
Indirect (back–calculated)			1.4 (0.029, 70.)
Pooled (network)	43.3%		1.1 (0.020, 48.)

Gefitinib vs Chemotherapy

76			5.3e+06 (0.00059, 4.7e+16)
Pooled (pair–wise)			5.3e+05 (0.70, 2.2e+21)
Indirect (back–calculated)			0.62 (0.0030, 1.3e+02)
Pooled (network)	43.6%		1.1 (0.0096, 3.2e+02)

Osimertinib vs Chemotherapy

42			3.8e+08 (0.00046, 3.1e+20)
Pooled (pair–wise)			3.3e+07 (1.5, 1.9e+24)
Indirect (back–calculated)			1.3 (0.028, 58.)
Pooled (network)	47.5%		1.8 (0.064, 1.2e+02)

Erlotinib vs Dacomitinib

59			0.99 (0.028, 35.)
Pooled (pair–wise)			0.99 (0.015, 84.)
Indirect (back–calculated)			NA
Pooled (network)			0.98 (0.0094, 1.1e+02)

0.1   1   10

Study	I^2	Odds Ratio (95% CrI)
Erlotinib_chemotherapy vs Erlotinib		
67		0.37 (0.018, 7.4)
Pooled (pair−wise)		0.41 (0.0058, 13.)
Indirect (back−calculated)		NA
Pooled (network)		0.37 (0.0038, 22.)
Erlotinib_HER3i vs Erlotinib		
62		1.3e+10 (0.00014, 1.3e+24)
Pooled (pair−wise)		2.2e+07 (2.9, 1.3e+23)
Indirect (back−calculated)		NA
Pooled (network)		2.6e+08 (1.1, 2.5e+28)
Erlotinib_IGF_1Ri vs Erlotinib		
44		1.0 (0.029, 35.)
Pooled (pair−wise)		1.0 (0.015, 75.)
Indirect (back−calculated)		NA
Pooled (network)		0.97 (0.0095, 95.)
Erlotinib_METi vs Erlotinib		
12		1.6 (0.22, 12.)
7		1.6 (0.22, 12.)
Pooled (pair−wise)	0.0%	1.5 (0.18, 15.)
Indirect (back−calculated)		NA
Pooled (network)	0.0%	1.6 (0.12, 22.)
Erlotinib_MMPi vs Erlotinib		
21		5.8e+07 (1.7e−05, 1.9e+20)
Pooled (pair−wise)		5.4e+06 (0.97, 3.9e+23)
Indirect (back−calculated)		NA
Pooled (network)		6.5e+05 (0.57, 1.3e+20)

0.1   1   10

Study	I^2		Odds Ratio (95% CrI)

Erlotinib_antiangio vs Erlotinib

16			9.8e+08 (0.00042, 2.3e+21)
25			1.0 (0.23, 4.4)
33			1.6e−12 (2.1e−29, 1.3e+05)
34			1.0 (0.028, 36.)
35			4.4e+08 (6.0e−05, 3.2e+21)
Pooled (pair−wise)	31.4%		1.4 (0.30, 8.8)
Indirect (back−calculated)			NA
Pooled (network)	32.1%		1.5 (0.23, 12.)

Placebo vs Erlotinib

30			3.2e−12 (2.2e−29, 4.5e+05)
46			4.0e−12 (2.5e−29, 6.4e+05)
58			3.7e−12 (3.5e−29, 3.8e+05)
Pooled (pair−wise)	0.0%		3.0e−14 (1.6e−33, 0.052)
Indirect (back−calculated)			0.30 (0.015, 6.1)
Pooled (network)	35.2%		0.24 (0.0080, 3.3)

antiangio vs Erlotinib

28			4.3e+07 (0.00040, 4.8e+18)
Pooled (pair−wise)			5.2e+06 (5.0, 1.0e+31)
Indirect (back−calculated)			NA
Pooled (network)			2.8e+06 (4.1, 1.0e+20)

Osimertinib vs Gefitinib_Erlotinib

31			11. (0.80, 1.6e+02)
Pooled (pair−wise)			11. (0.42, 8.2e+02)
Indirect (back−calculated)			NA
Pooled (network)			11. (0.26, 1.0e+03)

0.1   1   10

Study	I^2		Odds Ratio (95% CrI)

Gefitinib_chemotherapy vs Gefitinib

49			4.9e+07 (0.00015, 1.6e+19)
Pooled (pair−wise)			4.2e+05 (0.67, 1.4e+20)
Indirect (back−calculated)			NA
Pooled (network)			1.6e+07 (0.79, 1.2e+21)

Gefitinib_PARPi vs Gefitinib

63			4.8e+07 (0.00014, 1.6e+19)
Pooled (pair−wise)			2.7e+07 (1.1, 9.9e+25)
Indirect (back−calculated)			NA
Pooled (network)			1.4e+06 (0.35, 5.5e+19)

Icotinib vs Gefitinib

55			2.8e+08 (0.00076, 1.0e+20)
Pooled (pair−wise)			2.1e+07 (5.6, 1.3e+21)
Indirect (back−calculated)			NA
Pooled (network)			2.9e+06 (5.9, 3.4e+19)

Lazertinib vs Gefitinib

r17			1.7e+08 (5.6e−05, 5.4e+20)
Pooled (pair−wise)			1.6e+08 (0.74, 1.4e+22)
Indirect (back−calculated)			0.59 (0.0027, 1.3e+02)
Pooled (network)	41.5%		1.3 (0.010, 3.7e+02)

Osimertinib vs Lazertinib

r1			4.0 (0.19, 84.)
Pooled (pair−wise)			4.0 (0.085, 1.8e+02)
Indirect (back−calculated)			0.00013 (4.3e−09, 3.9)
Pooled (network)	72.4%		1.1 (0.026, 34.)

0.1   1   10

Study	I^2		Odds Ratio (95% CrI)

Osimertinib_chemotherapy vs Osimertinib

r16		←——————→	3.9e+07 (0.0025, 6.3e+17)
Pooled (pair−wise)		←1.2e+10	1.2e+10 (28., 2.5e+26)
Indirect (back−calculated)			NA
Pooled (network)		——→	4.5e+05 (3.3, 6.3e+19)

Osimertinib_antiangio vs Osimertinib

8		←——————→	2.0e+08 (0.0019, 2.1e+19)
Pooled (pair−wise)		———→	1.4e+08 (2.2, 4.0e+20)
Indirect (back−calculated)			NA
Pooled (network)		———→	3.9e+05 (1.6, 1.2e+16)

Placebo vs Osimertinib

10		——o——→	1.6 (0.22, 12.)
r19		←——————→	4.7e−12 (3.4e−29, 6.4e+05)
Pooled (pair−wise)	51.0%	←—■—→	0.87 (0.042, 10.)
Indirect (back−calculated)			NA
Pooled (network)	86.3%	←■——	0.14 (0.0031, 1.9)

0.1   1   10